Journal of the American Pharmacists Association
Fecha de publicación: 14 june 2018
Autores: Shellie L. Keast, Bethany Holderread, Terry Cothran, Grant H. Skrepnek
Background: The market for chronic hepatitis C (HCV) treatment has changed rapidly. New treatments offer high cure rates, fewer adverse effects, and shorter treatments—but also increased costs per therapy. The objective of this study was to compare adherence and cost between HCV patients included in an enhanced prior authorization and management program (PAMP) versus no intervention in Medicaid members undergoing treatment.